Related Experiment Video

Updated: May 17, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Cutl1: a potential target for cancer therapy

Kuan-can Liu1, Bao-shun Lin, Meng Zhao

  • 1Institute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, Fujian 350025, PR China.

Cellular Signalling
|October 23, 2012
PubMed

Insights

CDP (Cutl1) regulates gene expression and influences development and cancer. This review highlights its role in tumor progression, suggesting down-regulating Cut1 as a potential cancer therapy.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • CDP, encoded by the Cutl1 gene, is a transcription regulator influencing gene expression via DNA-binding.
  • CDP activity is modulated by various modifications (transcriptional, posttranscriptional, translational, posttranslational).

Purpose of the Study:

  • To systematically analyze the role of CDP in normal development and tumor progression.
  • To emphasize CDP's interactors and downstream molecules.
  • To evaluate Cut1 as a therapeutic target in cancer.

Main Methods:

  • Literature review of studies on CDP/Cutl1.
  • Analysis of CDP's involvement in normal development.
  • Examination of CDP's role in tumor progression, including its interactors and downstream targets.

Main Results:

  • CDP plays a dual role in gene expression, acting as both a repressor and promoter.
  • CDP is implicated in both normal development and the progression of various cancers.
  • Specific interactors and downstream molecules of CDP involved in cancer were identified.

Conclusions:

  • Cut1 (CDP) promotes cancer progression.
  • Down-regulating Cut1 expression presents a promising therapeutic strategy for cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...